Search
LENZ Therapeutics Inc
LENZAdd to Watchlist
5.890USD
+0.100+1.73%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
184.68MMarket Cap
LossP/E TTM
More Details of LENZ Therapeutics Inc Company
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
LENZ Therapeutics Inc Info
Ticker SymbolLENZ
Company nameLENZ Therapeutics Inc
IPO dateJun 25, 2021
CEOSchimmelpennink (Evert)
Number of employees42
Security typeOrdinary Share
Fiscal year-endJun 25
Address- -
City- -
Stock exchangeNASDAQ OMX - NASDAQ BASIC
Country- -
Postal code- -
Phone- -
Website- -
Ticker SymbolLENZ
IPO dateJun 25, 2021
CEOSchimmelpennink (Evert)
Company Executives of LENZ Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
--
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
--
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
FAQs
Who are the top five shareholders of LENZ Therapeutics Inc?
The top five shareholders of LENZ Therapeutics Inc are: Mr. James Mccollum
How many institutions hold shares of LENZ Therapeutics Inc (LENZ)?
As of 2026Q1, 347 institutions hold shares of LENZ Therapeutics Inc, with a combined market value of approximately 36.30M, accounting for 115.82% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 853081.00.